Company / Cost of Revenue
REGENXBIO Inc. Cost of Revenue History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$33.6M
FY2024
5-year range
$8.2M / $54.5M
FY2020-FY2024
Trend
-9.8%
vs FY2023
Sector context
#59 of 85
Health Care
What the data says
At $34M, REGENXBIO Inc.'s cost of revenue ranks #27 of 85 in the Health Care sector. Cost of Revenue has fluctuated over the past 9 years, ranging from $122,000 in FY2016 to $55M in FY2022.
Based on SEC 10-K filings.
$34M in FY2024 with a 5-year CAGR of +81.4%.
Improved from $55M to $34M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +59.7%
- 5-Year CAGR
- +81.4%
- 10-Year CAGR
- -
Sector benchmark
#27 of 85 in Health CareTop 31% of 85This company $33.6M Sector average $2.0B
▼
-98.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +81.4%, indicating consistent growth.
- In FY2024, cost of revenue decreased 9.8% year-over-year.
- Ranks #59 out of 85 companies in the Health Care sector.
- Peak cost of revenue was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -2.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $33.6M | -9.8% |
| FY2023 | $37.2M | -31.8% |
| FY2022 | $54.5M | +561.9% |
| FY2021 | $8.2M | -14.5% |
| FY2020 | $9.6M | +464.1% |
| FY2019 | $1.7M | -82.3% |
| FY2018 | $9.6M | +464.1% |
| FY2017 | $1.7M | +1300.8% |
| FY2016 | $122.0K | -29.5% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026